This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Diabetes, Gestational
+3

Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes

Sponsored by Jaeb Center for Health Research

About this trial

Last updated a year ago

Study ID

INHALE-GDM

Status

Not yet recruiting

Type

Interventional

Phase

Phase 2/Phase 3

Placebo

No

Accepting

18-75 Years
18 to 49 Years
Female
Female

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 8 months ago

What is this trial about?

Pregnant women aged 18-49 with gestational diabetes (GDM) will take part in this study. We want to see how two different insulin treatments affect their blood sugar after they eat. These women usually use a rapid-acting insulin analog (RAA) that's injected to control their blood sugar before and after meals. They will come to the clinic for two meal sessions. For the first meal, we will randomly decide if they will use the usual RAA insulin or a newer inhaled insulin called technosphere insulin (TI). They will use the other type of insulin for their second meal. After each meal, we will compare their blood sugar levels.

What are the participation requirements?

Yes

Inclusion Criteria

1. Ability to provide informed consent for study participation

2. Age ≥18 years and <50 years old

3. Singleton pregnancy at 24-34 weeks gestation

4. Diagnosis of GDM via standard 1-step or 2-step criteria

5. Treated with an insulin regimen that includes a RAA bolus of any type for breakfast, with a dose <20 units

6. Pre-pregnancy or first trimester body mass index (BMI) 25-45

7. Peak expiratory flow ≥80% predicted as measured by peak flow meter

8. Investigator believes that the protocol can be safely conducted by the participant

9. Able to read and speak English

No

Exclusion Criteria

1. Type 1 diabetes or type 2 diabetes

2. HbA1c ≥ 6.5%, FBG ≥125 mg/dl or 2-hr glucose ≥200 mg/dL on 75g OGTT, or random plasma glucose ≥200 mg/dL (consistent with pre-existing diabetes and not GDM diagnosis)

3. Current use of any non-insulin glucose lowering medication

4. Using TI (Afrezza), regular insulin or ≥20 RAA units at breakfast

5. Recent history of asthma (defined as using any medications to treat asthma within the last year), chronic obstructive pulmonary disease (COPD), or any other clinically important pulmonary disease (e.g., cystic fibrosis or bronchopulmonary dysplasia), or significant congenital or acquired cardiopulmonary disease as judged by the Investigator

6. Smoking (includes cigarettes, cigars, pipes, and/or vaping devices) within 90 days prior to screening

7. History or current diagnosis of lung cancer

8. Current or anticipated use of oral, inhaled or injectable glucocorticoids during the time period of the trial (topical glucocorticoid use is acceptable)

9. Being a member of the study team, having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study Investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial

Locations

Location

Status